{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35936217", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "09"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "11"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "29"}], "Language": ["eng"], "ELocationID": ["2493053", "10.1155/2022/2493053"], "Journal": {"ISSN": "1942-0994", "JournalIssue": {"Volume": "2022", "PubDate": {"Year": "2022"}}, "Title": "Oxidative medicine and cellular longevity", "ISOAbbreviation": "Oxid Med Cell Longev"}, "ArticleTitle": "Clinical Evidence of Acetyl-L-Carnitine Efficacy in the Treatment of Acute Ischemic Stroke: A Pilot Clinical Trial.", "Pagination": {"StartPage": "2493053", "MedlinePgn": "2493053"}, "Abstract": {"AbstractText": ["This study was undertaken to evaluate the influence of oral Acetyl-L-carnitine (ALC) in patients with acute ischemic stroke.", "Sixty-nine cases with acute ischemic stroke with the onset of symptoms less than 24 hours not candidates for reperfusion therapy were randomly assigned to either the ALC group (1000\u2009mg three times per day for three consecutive days) or the matching placebo group. The study outcomes based on intention-to-treat criteria included the change in the modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) score from baseline to day 90, as well as the change in serum levels of the inflammatory and oxidative stress biomarkers over the 3-day treatment protocol.", "The NIHSS score and mRS score on day 90 were improved by 5.82 and 0.94 scores, respectively, in the ALC-treated group compared to 2.83 and 0.11 scores, respectively, in the placebo-treated group, which demonstrated the superiority of ALC relative to placebo. By using the multivariable analysis after adjusting for other variables in the model, compared to the group treated with placebo, patients in the ALC group had lower NIHSS score (<i>\u03b2</i>: -2.40, 95% CI: -0.69, -4.10 (<i>p</i> = 0.007)) and mRS score (<i>\u03b2</i>: -1.18, 95% CI: -0.52, -1.84 (<i>p</i> = 0.001)) 90 days after the intervention. The percentage of patients with a favourable functional outcome at day 90, defined as mRS scores of 0 or 1, was significantly higher in the ALC group in comparison to the placebo group (52.9% versus 28.6%). Further, over the 3-day treatment protocol, in the patients receiving ALC, the serum levels of proinflammatory biomarkers, including soluble intercellular adhesion molecule-1 (sICAM-1), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-<i>\u03b1</i>), and neuron-specific enolase (NSE), showed a significant decrease, while the serum levels of antioxidant biomarkers, including glutathione peroxidase (GPx), superoxide dismutase (SOD), and total antioxidant capacity (TAC), as well as the total L-carnitine's level showed a significant increase compared to those in patients receiving placebo indicating significant alteration.", "Although preliminary, these results suggested that ALC administration during the acute phase of ischemic stroke might be helpful in improving functional and neurological outcomes that are probably linked to its anti-inflammatory and antioxidant properties. <i>Trial Registration</i>. This trial is registered with IRCT20150629022965N17 at Iranian Registry of Clinical Trials (registration date: 25/07/2018)."], "CopyrightInformation": "Copyright \u00a9 2022 Mehrdokht Mazdeh et al."}, "AuthorList": [{"Identifier": ["0000-0001-6253-5850"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Mazdeh", "ForeName": "Mehrdokht", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Abolfathi", "ForeName": "Parnaz", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Sabetghadam", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": ["0000-0001-7521-4909"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Modeling of Noncommunicable Diseases Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Mohammadi", "ForeName": "Younes", "Initials": "Y"}, {"Identifier": ["0000-0003-4119-1600"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Mehrpooya", "ForeName": "Maryam", "Initials": "M"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Oxid Med Cell Longev", "NlmUniqueID": "101479826", "ISSNLinking": "1942-0994"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Biomarkers"}, {"RegistryNumber": "6DH1W9VH8Q", "NameOfSubstance": "Acetylcarnitine"}], "MeshHeadingList": [{"QualifierName": ["therapeutic use"], "DescriptorName": "Acetylcarnitine"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antioxidants"}, {"QualifierName": [], "DescriptorName": "Biomarkers"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Brain Ischemia"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Iran"}, {"QualifierName": [], "DescriptorName": "Ischemic Stroke"}, {"QualifierName": [], "DescriptorName": "Stroke"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}], "CoiStatement": "The authors declare that they have no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Roger V. L., Go A. S., Lloyd-Jones D. M., et al. Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation . 2012;125(1):188\u2013197. doi: 10.1161/CIR.0b013e3182456d46.", "ArticleIdList": ["10.1161/CIR.0b013e3182456d46", "22215894"]}, {"Citation": "Yang Y., Shi Y. Z., Zhang N., et al. The disability rate of 5-year post-stroke and its correlation factors: a National Survey in China. PLoS One . 2016;11(11, article e0165341) doi: 10.1371/journal.pone.0165341.", "ArticleIdList": ["10.1371/journal.pone.0165341", "PMC5100878", "27824877"]}, {"Citation": "Morales-Vidal S., Biller J. Stroke Management and Recovery . Future Medicine Ltd; 2013. Stroke pathophysiology; pp. 6\u201320."}, {"Citation": "Hanley D., Hacke W. Critical care and emergency medicine neurology in stroke. Stroke . 2005;36(2):205\u2013207. doi: 10.1161/01.STR.0000154923.27548.69.", "ArticleIdList": ["10.1161/01.STR.0000154923.27548.69", "15653573"]}, {"Citation": "Jin R., Liu L., Zhang S., Nanda A., Li G. Role of inflammation and its mediators in acute ischemic stroke. Journal of Cardiovascular Translational Research . 2013;6(5):834\u2013851. doi: 10.1007/s12265-013-9508-6.", "ArticleIdList": ["10.1007/s12265-013-9508-6", "PMC3829610", "24006091"]}, {"Citation": "Adibhatla R. M., Hatcher J. F. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxidants & Redox Signaling . 2010;12(1):125\u2013169. doi: 10.1089/ars.2009.2668.", "ArticleIdList": ["10.1089/ars.2009.2668", "19624272"]}, {"Citation": "Chan P. H. Role of oxidants in ischemic brain damage. Stroke . 1996;27(6):1124\u20131129. doi: 10.1161/01.STR.27.6.1124.", "ArticleIdList": ["10.1161/01.STR.27.6.1124", "8650725"]}, {"Citation": "Drieu A., Levard D., Vivien D., Rubio M. Anti-inflammatory treatments for stroke: from bench to bedside. Therapeutic Advances in Neurological Disorders . 2018;11:p. 175628641878985. doi: 10.1177/1756286418789854.", "ArticleIdList": ["10.1177/1756286418789854", "PMC6066814", "30083232"]}, {"Citation": "Iadecola C., Anrather J. The immunology of stroke: from mechanisms to translation. Nature Medicine . 2011;17(7):796\u2013808. doi: 10.1038/nm.2399.", "ArticleIdList": ["10.1038/nm.2399", "PMC3137275", "21738161"]}, {"Citation": "Smith C. J., Emsley H. C., Gavin C. M., et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology . 2004;4(1):p. 2. doi: 10.1186/1471-2377-4-2.", "ArticleIdList": ["10.1186/1471-2377-4-2", "PMC331413", "14725719"]}, {"Citation": "Zhang R. L., Chopp M., Li Y., et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology . 1994;44(9):1747\u20131751. doi: 10.1212/WNL.44.9.1747.", "ArticleIdList": ["10.1212/WNL.44.9.1747", "7936308"]}, {"Citation": "Yamasaki Y., Matsuura N., Shozuhara H., Onodera H., Itoyama Y., Kogure K. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke . 1995;26(4):676\u2013681. doi: 10.1161/01.STR.26.4.676.", "ArticleIdList": ["10.1161/01.STR.26.4.676", "7709417"]}, {"Citation": "Yang G.-Y., Gong C., Qin Z., Ye W., Mao Y., Bertz A. L. Inhibition of TNF\u03b1 attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport . 1998;9(9):2131\u20132134. doi: 10.1097/00001756-199806220-00041.", "ArticleIdList": ["10.1097/00001756-199806220-00041", "9674607"]}, {"Citation": "Nilupul Perera M., Ma H. K., Arakawa S., et al. Inflammation following stroke. Journal of Clinical Neuroscience . 2006;13(1):1\u20138. doi: 10.1016/j.jocn.2005.07.005.", "ArticleIdList": ["10.1016/j.jocn.2005.07.005", "16410192"]}, {"Citation": "Tewari A., Mahendru V., Sinha A., Bilotta F. Antioxidants: the new frontier for translational research in cerebroprotection. Journal of anaesthesiology, clinical pharmacology . 2014;30(2):160\u2013171. doi: 10.4103/0970-9185.130001.", "ArticleIdList": ["10.4103/0970-9185.130001", "PMC4009632", "24803750"]}, {"Citation": "Jones L. L., McDonald D. A., Borum P. R. Acylcarnitines: role in brain. Progress in Lipid Research . 2010;49(1):61\u201375. doi: 10.1016/j.plipres.2009.08.004.", "ArticleIdList": ["10.1016/j.plipres.2009.08.004", "19720082"]}, {"Citation": "Calvani M., Reda E., Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Research in Cardiology . 2000;95(2):75\u201383. doi: 10.1007/s003950050167.", "ArticleIdList": ["10.1007/s003950050167", "10826498"]}, {"Citation": "Shug A. L., Schmidt M. J., Golden G. T., Fariello R. G. The distribution and role of carnitine in the mammalian brain. Life Sciences . 1982;31(25):2869\u20132874. doi: 10.1016/0024-3205(82)90677-4.", "ArticleIdList": ["10.1016/0024-3205(82)90677-4", "7162355"]}, {"Citation": "Parnetti L., Gaiti A., Mecocci P., Cadini D., Senin U. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. European Journal of Clinical Pharmacology . 1992;42(1):89\u201393. doi: 10.1007/BF00314926.", "ArticleIdList": ["10.1007/BF00314926", "1541322"]}, {"Citation": "Pettegrew J., Levine J., McClure R. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Molecular Psychiatry . 2000;5(6):616\u2013632. doi: 10.1038/sj.mp.4000805.", "ArticleIdList": ["10.1038/sj.mp.4000805", "11126392"]}, {"Citation": "Goety C. G., Tanner C. M., Cohen J. A., et al. L-Acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Movement disorders : official journal of the Movement Disorder Society . 1990;5(3):263\u2013265.", "ArticleIdList": ["2143808"]}, {"Citation": "Malaguarnera M., Gargante M. P., Cristaldi E., et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Digestive Diseases and Sciences . 2008;53(11):3018\u20133025. doi: 10.1007/s10620-008-0238-6.", "ArticleIdList": ["10.1007/s10620-008-0238-6", "18357530"]}, {"Citation": "Veronese N., Stubbs B., Solmi M., Ajnakina O., Carvalho A. F., Maggi S. Acetyl-l-carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis. Psychosomatic Medicine . 2018;80(2):154\u2013159. doi: 10.1097/PSY.0000000000000537.", "ArticleIdList": ["10.1097/PSY.0000000000000537", "29076953"]}, {"Citation": "Wainwright M. S., Kohli R., Whitington P. F., Chace D. H. Carnitine treatment inhibits increases in cerebral carnitine esters and glutamate detected by mass spectrometry after hypoxia-ischemia in newborn rats. Stroke . 2006;37(2):524\u2013530. doi: 10.1161/01.STR.0000198892.15269.f7.", "ArticleIdList": ["10.1161/01.STR.0000198892.15269.f7", "16385097"]}, {"Citation": "Jalal F. Y., B\u00f6hlke M., Maher T. J. Acetyl-l-carnitine reduces the infarct size and striatal glutamate outflow following focal cerebral ischemia in rats. Annals of the New York Academy of Sciences . 2010;1199(1):95\u2013104. doi: 10.1111/j.1749-6632.2009.05351.x.", "ArticleIdList": ["10.1111/j.1749-6632.2009.05351.x", "20633114"]}, {"Citation": "Powers W. J., Rabinstein A. A., Ackerson T., et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke . 2018;49(3):e46\u2013e110. doi: 10.1161/STR.0000000000000158.", "ArticleIdList": ["10.1161/STR.0000000000000158", "29367334"]}, {"Citation": "Muir K. W., Weir C. J., Murray G. D., Povey C., Lees K. R. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke . 1996;27(10):1817\u20131820. doi: 10.1161/01.STR.27.10.1817.", "ArticleIdList": ["10.1161/01.STR.27.10.1817", "8841337"]}, {"Citation": "Van Swieten J., Koudstaal P., Visser M., Schouten H., Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke . 1988;19(5):604\u2013607. doi: 10.1161/01.STR.19.5.604.", "ArticleIdList": ["10.1161/01.STR.19.5.604", "3363593"]}, {"Citation": "Bonaventura A., Liberale L., Vecchi\u00e9 A., et al. Update on inflammatory biomarkers and treatments in ischemic stroke. International Journal of Molecular Sciences . 2016;17(12):p. 1967. doi: 10.3390/ijms17121967.", "ArticleIdList": ["10.3390/ijms17121967", "PMC5187767", "27898011"]}, {"Citation": "Benzie I. F., Szeto Y. Total antioxidant capacity of teas by the ferric reducing/antioxidant power assay. Journal of Agricultural and Food Chemistry . 1999;47(2):633\u2013636. doi: 10.1021/jf9807768.", "ArticleIdList": ["10.1021/jf9807768", "10563944"]}, {"Citation": "Ellman G. L. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics . 1959;82(1):70\u201377. doi: 10.1016/0003-9861(59)90090-6.", "ArticleIdList": ["10.1016/0003-9861(59)90090-6", "13650640"]}, {"Citation": "Botsoglou N. A., Fletouris D. J., Papageorgiou G. E., Vassilopoulos V. N., Mantis A. J., Trakatellis A. G. Rapid, sensitive, and specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food, and feedstuff samples. Journal of Agricultural and Food Chemistry . 1994;42(9):1931\u20131937. doi: 10.1021/jf00045a019.", "ArticleIdList": ["10.1021/jf00045a019"]}, {"Citation": "Unnebrink K., Windeler J. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Statistics in Medicine . 2001;20(24):3931\u20133946. doi: 10.1002/sim.1149.", "ArticleIdList": ["10.1002/sim.1149", "11782044"]}, {"Citation": "Sims N. R., Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease . 2010;1802(1):80\u201391. doi: 10.1016/j.bbadis.2009.09.003.", "ArticleIdList": ["10.1016/j.bbadis.2009.09.003", "19751827"]}, {"Citation": "Moghaddas A., Dashti-Khavidaki S. Potential protective effects of l-carnitine against neuromuscular ischemia-reperfusion injury: from experimental data to potential clinical applications. Clinical Nutrition . 2016;35(4):783\u2013790. doi: 10.1016/j.clnu.2015.07.001.", "ArticleIdList": ["10.1016/j.clnu.2015.07.001", "26199084"]}, {"Citation": "Rosenthal R. E., Williams R., Bogaert Y. E., Getson P. R., Fiskum G. Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine. Stroke . 1992;23(9):1312\u20131317. doi: 10.1161/01.STR.23.9.1312.", "ArticleIdList": ["10.1161/01.STR.23.9.1312", "1519288"]}, {"Citation": "Aureli T., Miccheli A., Di Cocco M. E., et al. Effect of acetyl-l-carnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat -- study by 13P- and 1H-NMR spectroscopy. Brain Research . 1994;643(1-2):92\u201399. doi: 10.1016/0006-8993(94)90013-2.", "ArticleIdList": ["10.1016/0006-8993(94)90013-2", "8032936"]}, {"Citation": "Cassol G., Godinho D. B., de Zorzi V. N., et al. Potential therapeutic implications of ergogenic compounds on pathophysiology induced by traumatic brain injury: a narrative review. Life Sciences . 2019;233, article 116684 doi: 10.1016/j.lfs.2019.116684.", "ArticleIdList": ["10.1016/j.lfs.2019.116684", "31351083"]}, {"Citation": "Malaguarnera M., Vacante M., Giordano M., et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. The American Journal of Clinical Nutrition . 2011;93(4):799\u2013808. doi: 10.3945/ajcn.110.007393.", "ArticleIdList": ["10.3945/ajcn.110.007393", "21310833"]}, {"Citation": "Rao K. R., Mawal Y. R., Qureshi I. A. Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: role of acetyl-l-carnitine in restoring the ammonia-induced cerebral energy depletion1. Neuroscience Letters . 1997;224(2):83\u201386. doi: 10.1016/S0304-3940(97)13476-0.", "ArticleIdList": ["10.1016/S0304-3940(97)13476-0", "9086462"]}, {"Citation": "Binienda Z., Virmani A., Przybyla-Zawislak B., Schmued L. Neuroprotective effect of L-carnitine in the 3-nitropropionic acid (3-NPA)-evoked neurotoxicity in rats. Neuroscience Letters . 2004;367(2):264\u2013267. doi: 10.1016/j.neulet.2004.05.031.", "ArticleIdList": ["10.1016/j.neulet.2004.05.031", "15331167"]}, {"Citation": "Zanelli S. A., Solenski N. J., Rosenthal R. E., Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-L-carnitine. Annals of the New York Academy of Sciences . 2005;1053(1):153\u2013161. doi: 10.1196/annals.1344.013.", "ArticleIdList": ["10.1196/annals.1344.013", "PMC4454400", "16179519"]}, {"Citation": "Ishii T., Shimpo Y., Matsuoka Y., Kinoshita K. Anti-apoptotic effect of acetyl-/-carnitine and l-carnitine in primary cultured neurons. The Japanese Journal of Pharmacology . 2000;83(2):119\u2013124. doi: 10.1016/S0021-5198(19)30606-7.", "ArticleIdList": ["10.1016/S0021-5198(19)30606-7", "10928324"]}, {"Citation": "Zhu X., Sato E. F., Wang Y., Nakamura H., Yodoi J., Inoue M. Acetyl-L-carnitine suppresses apoptosis of thioredoxin 2-deficient DT40 cells. Archives of Biochemistry and Biophysics . 2008;478(2):154\u2013160. doi: 10.1016/j.abb.2008.07.024.", "ArticleIdList": ["10.1016/j.abb.2008.07.024", "18713618"]}, {"Citation": "Traina G. The neurobiology of acetyl-L-carnitine. Frontiers in Bioscience-Landmark . 2016;21(7):1314\u20131329. doi: 10.2741/4459.", "ArticleIdList": ["10.2741/4459", "27100509"]}, {"Citation": "Surai P. F. Antioxidant action of carnitine: molecular mechanisms and practical applications. EC Veterinary Science . 2015;2(1):66\u201384."}, {"Citation": "Zidan A., Hedya S. E., Elfeky D. M., Abdin A. A. The possible anti-apoptotic and antioxidant effects of acetyl l-carnitine as an add-on therapy on a relapsing-remitting model of experimental autoimmune encephalomyelitis in rats. Biomedicine & Pharmacotherapy . 2018;103:1302\u20131311. doi: 10.1016/j.biopha.2018.04.173.", "ArticleIdList": ["10.1016/j.biopha.2018.04.173", "29864912"]}, {"Citation": "Yu J., Ye J., Liu X., Han Y., Wang C. Protective effect of L-carnitine against H2O2-induced neurotoxicity in neuroblastoma (SH-SY5Y) cells. Neurological Research . 2011;33(7):708\u2013716. doi: 10.1179/1743132810Y.0000000028.", "ArticleIdList": ["10.1179/1743132810Y.0000000028", "21756550"]}, {"Citation": "Liu Y., Rosenthal R. E., Starke-Reed P., Fiskum G. Inhibition of postcardiac arrest brain protein oxidation by acetyl-L-carnitine. Free Radical Biology and Medicine . 1993;15(6):667\u2013670. doi: 10.1016/0891-5849(93)90171-P.", "ArticleIdList": ["10.1016/0891-5849(93)90171-P", "8138193"]}, {"Citation": "Calabrese V., Ravagna A., Colombrita C., et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. Journal of Neuroscience Research . 2005;79(4):509\u2013521. doi: 10.1002/jnr.20386.", "ArticleIdList": ["10.1002/jnr.20386", "15641110"]}, {"Citation": "Liu J., Head E., Kuratsune H., Cotman C. W., Ames B. N. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Annals of the New York Academy of Sciences . 2004;1033(1):117\u2013131. doi: 10.1196/annals.1320.011.", "ArticleIdList": ["10.1196/annals.1320.011", "15591009"]}, {"Citation": "Zhang R., Zhang H., Zhang Z., et al. Neuroprotective effects of pre-treament with l-carnitine and acetyl-l-carnitine on ischemic injury in vivo and in vitro. International Journal of Molecular Sciences . 2012;13(2):2078\u20132090. doi: 10.3390/ijms13022078.", "ArticleIdList": ["10.3390/ijms13022078", "PMC3292008", "22408439"]}, {"Citation": "Calabrese V., Scapagnini G., Ravagna A., et al. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochemical Research . 2003;28(9):1321\u20131328. doi: 10.1023/A:1024984013069.", "ArticleIdList": ["10.1023/A:1024984013069", "12938853"]}, {"Citation": "Mohammadi H., Djalali M., Daneshpazhooh M., et al. Effects of L-carnitine supplementation on biomarkers of oxidative stress, antioxidant capacity and lipid profile, in patients with pemphigus vulgaris: a randomized, double-blind, placebo-controlled trial. European Journal of Clinical Nutrition . 2018;72(1):99\u2013104. doi: 10.1038/ejcn.2017.131.", "ArticleIdList": ["10.1038/ejcn.2017.131", "28832573"]}, {"Citation": "Lee B.-J., Lin J.-S., Lin Y.-C., Lin P.-T. Effects of L-carnitine supplementation on oxidative stress and antioxidant enzymes activities in patients with coronary artery disease: a randomized, placebo-controlled trial. Nutrition Journal . 2014;13(1):p. 79. doi: 10.1186/1475-2891-13-79.", "ArticleIdList": ["10.1186/1475-2891-13-79", "PMC4125592", "25092108"]}, {"Citation": "Liu T., Zhang L., Joo D., Sun S.-C. NF-\u03baB signaling in inflammation. Signal Transduction and Targeted Therapy . 2017;2(1):p. 17023. doi: 10.1038/sigtrans.2017.23.", "ArticleIdList": ["10.1038/sigtrans.2017.23", "PMC5661633", "29158945"]}, {"Citation": "Koc A., Ozkan T., Karabay A., Sunguroglu A., Aktan F. Effect of L-carnitine on the synthesis of nitric oxide in RAW 264\u00b77 murine macrophage cell line. Cell Biochemistry and Function . 2011;29(8):679\u2013685. doi: 10.1002/cbf.1807.", "ArticleIdList": ["10.1002/cbf.1807", "22012571"]}, {"Citation": "Lee B.-J., Lin J.-S., Lin Y.-C., Lin P.-T. Antiinflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition . 2015;31(3):475\u2013479. doi: 10.1016/j.nut.2014.10.001.", "ArticleIdList": ["10.1016/j.nut.2014.10.001", "25701337"]}, {"Citation": "Ponnusamy K., Babulogaiah S., Gopal N., Manavalan S. Acetyl-L-carnitine and quercetin as PARP-1 modulators: implication on Alzheimer\u2019s disease. Poster Presntation. The Lancet Neurology Conference Preclinical neurodegenerative disease: towards prevention and early diagnosis . 2016:19\u201321."}, {"Citation": "Frijns C., Kappelle L. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke . 2002;33(8):2115\u20132122. doi: 10.1161/01.STR.0000021902.33129.69.", "ArticleIdList": ["10.1161/01.STR.0000021902.33129.69", "12154274"]}, {"Citation": "Wang S.-X., Tan L., Wang J., Zhong J.-Q. Effect of levocarnitine on TIMP-1, ICAM-1 expression of rats with coronary heart disease and its myocardial protection effect. Asian Pacific Journal of Tropical Medicine . 2016;9(3):269\u2013273. doi: 10.1016/j.apjtm.2016.01.025.", "ArticleIdList": ["10.1016/j.apjtm.2016.01.025", "26972400"]}, {"Citation": "Lai T. W., Zhang S., Wang Y. T. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Progress in Neurobiology . 2014;115:157\u2013188. doi: 10.1016/j.pneurobio.2013.11.006.", "ArticleIdList": ["10.1016/j.pneurobio.2013.11.006", "24361499"]}, {"Citation": "Llansola M., Erceg S., Hern\u00e1ndez-Viadel M., Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metabolic Brain Disease . 2002;17(4):389\u2013397. doi: 10.1023/A:1021922305036.", "ArticleIdList": ["10.1023/A:1021922305036", "12602515"]}, {"Citation": "Forloni G., Angeretti N., Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. Journal of Neuroscience Research . 1994;37(1):92\u201396. doi: 10.1002/jnr.490370112.", "ArticleIdList": ["10.1002/jnr.490370112", "7908343"]}, {"Citation": "Chichanovskaya L., Bakhareva O., Sorokina K. A study of the efficacy and safety of L-carnitine in patients with ischemic stroke in the early rehabilitation period. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova . 2017;117(12):65\u201369. doi: 10.17116/jnevro201711712265-69.", "ArticleIdList": ["10.17116/jnevro201711712265-69", "29411748"]}, {"Citation": "Postiglione A., Soricelli A., Cicerano U., et al. Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct. Pharmacological Research . 1991;23(3):241\u2013246. doi: 10.1016/S1043-6618(05)80083-0.", "ArticleIdList": ["10.1016/S1043-6618(05)80083-0", "2068049"]}, {"Citation": "Kazemian K., Ala S., Mojtahedzadeh M., et al. Evaluation of neuroprtective effects of L-carnitine and fat emulsion in the CVA patients: a prospective, randomized, double blind, clinical trial. Iranian Journal of Pharmaceutical Research . 2020;19(1):111\u2013119. doi: 10.22037/ijpr.2020.1100952.", "ArticleIdList": ["10.22037/ijpr.2020.1100952", "PMC7462480", "32922474"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "1", "Day": "28"}, {"Year": "2022", "Month": "4", "Day": "16"}, {"Year": "2022", "Month": "7", "Day": "2"}, {"Year": "2022", "Month": "8", "Day": "8", "Hour": "3", "Minute": "45"}, {"Year": "2022", "Month": "8", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "29"}], "PublicationStatus": "epublish", "ArticleIdList": ["35936217", "PMC9355767", "10.1155/2022/2493053"]}}], "PubmedBookArticle": []}